<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="134634">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02100579</url>
  </required_header>
  <id_info>
    <org_study_id>STU00088239</org_study_id>
    <secondary_id>STU00088239</secondary_id>
    <nct_id>NCT02100579</nct_id>
  </id_info>
  <brief_title>Ultrasound-guided Adductor Canal Block for Total Knee Replacement</brief_title>
  <official_title>Ultrasound-guided Adductor Canal Block for Total Knee Replacement: a Randomized, Double-blind Placebo Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Total knee arthroplasty is associated with intense early postoperative pain. Fast track
      recovery programs including early therapy protocols and early hospital discharge are being
      implemented at various hospitals. The postoperative analgesic pain regimen should enhance
      functional recovery in addition to providing efficient analgesia with minimal side effects.
      Adductor canal blockade is commonly used to provide postoperative analgesia for total knee
      arthroplasty (TKA) surgery. The investigators hypothesize that an ultrasound guided adductor
      canal block will lower narcotic consumption and improved overall satisfaction compared to
      ultrasound guided sham block with normal saline (placebo) for patients undergoing minimally
      invasive TKA surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Opioid consumption</measure>
    <time_frame>72 hours</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale pain score</measure>
    <time_frame>4hr intervals up to 48hrs</time_frame>
    <safety_issue>No</safety_issue>
    <description>Visual Analog Scale pain score; 0 = no pain, 10 = excruciating pain) in the knee at rest and during activity recorded every 4 hours up to 48hrs following surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospitalization</measure>
    <time_frame>24 to 72 hrs</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Arthroplasty, Replacement, Knee</condition>
  <arm_group>
    <arm_group_label>Ulrasound-guided adductor canal block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ultrasound-guided adductor canal blockade with 10 ml of 0.25% bupivacaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ultrasound-guided adductor canal block</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Ultrasound-guided sham block with 10 ml of preservative free normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>10 ml of 0.25% bupivacaine</description>
    <arm_group_label>Ulrasound-guided adductor canal block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Preservative free normal saline</intervention_name>
    <description>10 ml of preservative free normal saline</description>
    <arm_group_label>Ultrasound-guided adductor canal block</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants 40 to 75 years old who are presenting for minimally invasive total knee
             arthroplasty under spinal anesthesia

        Exclusion Criteria:

          -  Patient refusal

          -  American Society of Anesthesiologists physical status classification of 4 or higher

          -  Pre-existing neuropathy in the femoral or sciatic distribution

          -  Coagulopathy

          -  Infection at the site

          -  Chronic opioid use (greater than 3 months)

          -  Pregnancy

          -  Medical conditions limiting physical therapy participation

          -  Any other contra-indication to regional anesthesia
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antoun Nader, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University, Feinberg School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark Kendall, MD</last_name>
    <phone>312-695-2528</phone>
    <email>m-kendall@northwestern.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 27, 2014</lastchanged_date>
  <firstreceived_date>March 25, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Antoun Nader</investigator_full_name>
    <investigator_title>Professor of Anesthesiology</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
